Aurinia Pharmaceuticals Stock Working Capital
| AUPH Stock | USD 9.12 0.14 1.56% |
Aurinia Pharmaceuticals fundamentals help investors to digest information that contributes to Aurinia Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aurinia Stock. The fundamental analysis module provides a way to measure Aurinia Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aurinia Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 347.6 M | 345.8 M | |
| Change In Working Capital | -5.6 M | -5.3 M |
Aurinia | Working Capital |
Aurinia Pharmaceuticals Company Working Capital Analysis
Aurinia Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Aurinia Pharmaceuticals Working Capital | 347.61 M |
Most of Aurinia Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aurinia Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aurinia Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Aurinia Pharmaceuticals is extremely important. It helps to project a fair market value of Aurinia Stock properly, considering its historical fundamentals such as Working Capital. Since Aurinia Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aurinia Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aurinia Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, Aurinia Pharmaceuticals has a Working Capital of 347.61 M. This is 18.33% lower than that of the Biotechnology sector and 35.46% lower than that of the Health Care industry. The working capital for all United States stocks is 76.48% higher than that of the company.
Aurinia Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aurinia Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aurinia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aurinia Pharmaceuticals by comparing valuation metrics of similar companies.Aurinia Pharmaceuticals is currently under evaluation in working capital category among its peers.
Aurinia Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aurinia Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aurinia Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Aurinia Fundamentals
| Return On Equity | -0.0578 | ||||
| Return On Asset | -0.0216 | ||||
| Profit Margin | (0.10) % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 143.18 M | ||||
| Shares Owned By Insiders | 7.20 % | ||||
| Shares Owned By Institutions | 42.66 % | ||||
| Number Of Shares Shorted | 5.53 M | ||||
| Price To Earning | (4.83) X | ||||
| Price To Book | 3.31 X | ||||
| Price To Sales | 5.83 X | ||||
| Revenue | 175.51 M | ||||
| Gross Profit | 83.38 M | ||||
| EBITDA | (63.05 M) | ||||
| Net Income | (78.02 M) | ||||
| Cash And Equivalents | 391.51 M | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 97.61 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 13.09 X | ||||
| Book Value Per Share | 2.71 X | ||||
| Cash Flow From Operations | (33.46 M) | ||||
| Short Ratio | 4.22 X | ||||
| Earnings Per Share | (0.15) X | ||||
| Target Price | 10.84 | ||||
| Number Of Employees | 300 | ||||
| Beta | 1.46 | ||||
| Market Capitalization | 1.29 B | ||||
| Total Asset | 548.06 M | ||||
| Retained Earnings | (942.32 M) | ||||
| Working Capital | 347.61 M | ||||
| Current Asset | 16.53 M | ||||
| Current Liabilities | 3.62 M | ||||
| Net Asset | 548.06 M |
About Aurinia Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aurinia Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aurinia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aurinia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:Check out Aurinia Pharmaceuticals Piotroski F Score and Aurinia Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.